About aclaris therapeutics inc - ACRS
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
ACRS At a Glance
Aclaris Therapeutics, Inc.
701 Lee Road
Wayne, Pennsylvania 19087
| Phone | 1-484-324-7933 | Revenue | 7.83M | |
| Industry | Pharmaceuticals: Major | Net Income | -64,923,000.00 | |
| Sector | Health Technology | Employees | 73 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ACRS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 47.14 |
| Price to Book Ratio | 3.519 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.818 |
| Enterprise Value to Sales | 35.815 |
| Total Debt to Enterprise Value | 0.008 |
ACRS Efficiency
| Revenue/Employee | 107,205.479 |
| Income Per Employee | -889,356.164 |
| Receivables Turnover | 1.406 |
| Total Asset Turnover | 0.041 |
ACRS Liquidity
| Current Ratio | 3.362 |
| Quick Ratio | 3.362 |
| Cash Ratio | 3.168 |
ACRS Profitability
| Gross Margin | 6.926 |
| Operating Margin | -943.969 |
| Pretax Margin | -829.581 |
| Net Margin | -829.581 |
| Return on Assets | -34.099 |
| Return on Equity | -50.204 |
| Return on Total Capital | -61.715 |
| Return on Invested Capital | -49.499 |
ACRS Capital Structure
| Total Debt to Total Equity | 2.053 |
| Total Debt to Total Capital | 2.011 |
| Total Debt to Total Assets | 1.319 |
| Long-Term Debt to Equity | 1.518 |
| Long-Term Debt to Total Capital | 1.488 |